Details of the Drug Combinations

General Information of This Drug (ID: DMLOS5R)

• Drug Name: BAY 80-6946 (DMLOS5R)
• Synonyms: Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS

Indication

Follicular lymphoma; ICD 11: 2A80; Status: Approved [1]; Non-hodgkin lymphoma; ICD 11: 2B33.5; Status: Approved [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bay 80-6946 + Romidepsin	DCAXH8V	Romidepsin	Lymphoma, T-Cell	[3]
Bay 80-6946 + Ibrutinib	DCGSZY3	Ibrutinib	Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)	[4]
BAY1163877 + Bay 80-6946	DCK32U7	BAY1163877	Advanced or Metastatic Solid Tumor	[5]
Degarelix + Bay 80-6946	DC21GOX	Degarelix	Prostate Cancer	[6]
Gemcitabine + Bay 80-6946	DC85H4S	Gemcitabine	Mature T-Cell and NK-Cell Neoplasm	[7]
Itraconazole + Bay 80-6946	DCQHHEM	Itraconazole	Medical Oncology	[8]
Rifampicin + Bay 80-6946	DCNACZB	Rifampicin	Medical Oncology	[8]
Vemurafenib + Bay 80-6946	DCBAW91	Vemurafenib	Thyroid Carcinoma	[9]
Venetoclax + Bay 80-6946	DCGR5B8	Venetoclax	Non-Hodgkin Lymphoma	[10]
Venetoclax + Bay 80-6946	DCTO2Z4	Venetoclax	Diffuse Large B Cell Lymphoma	[11]
Acalabrutinib + Bay 80-6946	DC02PGU	Acalabrutinib	Chronic Lymphocytic Leukemia (CLL)	[12]
Fulvestrant + Bay 80-6946	DCQ1NVR	Fulvestrant	Endometrial Cancer	[13]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT04233697) Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
• [4] ClinicalTrials.gov (NCT03581942) Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
• [5] ClinicalTrials.gov (NCT03517956) Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
• [6] ClinicalTrials.gov (NCT06218667) A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer
• [7] ClinicalTrials.gov (NCT03052933) Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
• [8] ClinicalTrials.gov (NCT02253420) COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
• [9] ClinicalTrials.gov (NCT04462471) Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
• [10] ClinicalTrials.gov (NCT03886649) Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
• [11] ClinicalTrials.gov (NCT04572763) Copanlisib Plus Venetoclax in R/R DLBCL
• [12] ClinicalTrials.gov (NCT04685915) Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
• [13] ClinicalTrials.gov (NCT05082025) Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations